KRAS and neoplasm: Therefore, inhibiting canonical KRAS signaling, or using combinations based on these inhibitors, sensitizes tumor cells to immune checkpoint inhibitors, presenting an opportunity to explore such concepts in clinical settings [28, 44, 45, 46, 47].